USFDA issues 3 observations for Zydus Lifesciences's Vadodara plant

"We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network," Zydus Lifesciences stated.

Published On 2022-03-11 09:06 GMT | Update On 2022-03-11 09:06 GMT

New Delhi: Zydus Lifesciences on Thursday said the US health regulator has issued three observations after inspecting its Jarod (Vadodara) based manufacturing facility. The US Food and Drug Administration (USFDA) inspected the injectable facility from February 24 to March 10, 2022.The inspection closed with three observations, the drug firm said in a regulatory filing."We are confident...

The inspection closed with three observations, the drug firm said in a regulatory filing.

"We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network," Zydus Lifesciences stated.

As per the US health regulator, an FDA Form 483 (observation) is issued to a firm's management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of Food Drug and Cosmetic (FD&C) Act and related Act.

USFDA issues its observations through Form 483 at the conclusion of an inspection if the investigators have observed any conditions that may violate current good manufacturing practices.

Read Also - Zydus to launch Desidustat breakthrough treatment for Anemia in CKD patients under brand name Oxemia

Cadila Pharmaceuticals Ltd. is the privately-held pharmaceutical company in India. Over the past seven decades, Zydus has been developing and manufacturing affordable medicines for patients around the world.

The innovation-led drug discovery processes ensure the health and well-being of people around the world. Our enhanced investment in innovation and a strong track record in research and development have produced medical miracles that have changed lives and made a profound impact on real life.

Being a care-focused, research-driven company, Cadila is committed to complying with the highest ethical standard in clinical research and medical practice. Cadila wants to be valued not only for our pharmaceutical products but also for the way we conduct our research and business activities.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

USFDA issues 3 observations for Zydus Lifesciences's Vadodara plant

Similar News